Breast Cancer
Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)
- Details
ClinicalTrials.gov ID:
NCT05645536
Diagnosis Type:
NA
USOR Number:
- Address
,
P: